Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PYPD vs SRZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PYPD Captures Overall Composite Edge (31.1 SELL vs 33.2 SELL), While SRZN Leads 3–2 on Growth & Valuation Pillars

PYPD Overall Winner 6-Pillar Tally: PYPD 2 – 3 SRZN (1 Tie) Matrix Metrics: PYPD 3 – 4 SRZN

As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Surrozen, Inc. Common (SRZN) on higher Unified Composite conviction (31.1/100 SELL vs. 33.2/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while SRZN wins 3–2 across the 6-pillar growth and valuation breakdown. PYPD trades at $6.50 (N/M Forward P/E, 0.0% operating margin) versus SRZN at $29.93 (N/M Forward P/E, -485.4% operating margin).

  • Composite vs. Pillar Nuance: While SRZN currently prints a higher short-term Unified Composite Score (33.2/100 SELL vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -485.4% operating margin) and revenue trajectory (+0.0% vs. +408.6% YoY).
  • Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both PYPD (31.1/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PYPD vs SRZN
PYPD NASDAQ Head-to-Head Winner
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.50
+5.63% 1D
Market Cap $132.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.88β · 59% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $5.81 · SMA50: $5.40
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.28β · 66% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.9% over 20 days), RSI 53
RSI-14: 53.1 · SMA20: $29.76 · SMA50: $26.28

6-Pillar Scorecard Institutional Category Breakdown (PYPD 2 – 3 SRZN)

Columns: Metric · PYPD · SRZN
1. Valuation Multiples SRZN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 48.3x
2. Growth & Scale SRZN
Revenue Growth (YoY) +0.0% +408.6%
Earnings Growth (YoY) +0.0% -37.0%
TTM Revenue (USD) N/A $11M
Market Cap $132.2M $602.5M
3. Profitability & Quality PYPD
Gross Margin N/A N/A
Operating Margin 0.0% -485.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -243.6% -62.8%
4. Balance Sheet & Cash Flow SRZN
Cash Generation (TTM) N/A -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.0M Net Cash $95M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PYPD
Options Structure Phase BREAKOUT CONSOLIDATION
Current IV / %ile 106.3% (12th %ile) 72.0% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PYPD (3) vs SRZN (4)
Institutional Metric PYPD SRZN Criterion Row Edge
Market Capitalization
Scale
$132.2M $602.5M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +408.6% Higher Growth SRZN
Operating Margin (TTM)
Profitability
0.0% -485.4% Higher Margin PYPD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-243.6% -62.8% Higher ROE SRZN
52-Week Range Position
Momentum
82% ($4–$7) 69% ($12–$38) Stronger Trend PYPD
Beta / 30D Volatility
Risk Regime
0.88β · 59% Vol 1.28β · 66% Vol Lower Realized Risk PYPD
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 33.2 / 100 (SELL) Higher Composite SRZN
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 48.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.0M Net Cash) -$31M ($95M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PYPD +7.55 pp
PYPD: +33.12% · SRZN: +25.57%
3M Horizon PYPD +4.98 pp
PYPD: +29.66% · SRZN: +24.68%
6M Horizon PYPD +19.4 pp
PYPD: +36.47% · SRZN: +17.07%
1Y Horizon SRZN +49.67 pp
PYPD: +80.95% · SRZN: +130.62%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs SRZN. Trailing 12-month operating profitability (PYPD 0.0% vs SRZN -485.4%) and valuation multiples (PYPD N/M vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PYPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-243.6% · N/M
SRZN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-485.4%
ROE / Fwd P/E-62.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PYPD BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV 106.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PYPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PYPD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PYPD vs SRZN Key Questions & Quantitative Answers

As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Surrozen, Inc. Common (SRZN) on higher Unified Composite conviction (31.1/100 SELL vs. 33.2/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while SRZN wins 3–2 across the 6-pillar growth and valuation breakdown. PYPD trades at $6.50 (N/M Forward P/E, 0.0% operating margin) versus SRZN at $29.93 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While SRZN currently prints a higher short-term Unified Composite Score (33.2/100 SELL vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -485.4% operating margin) and revenue trajectory (+0.0% vs. +408.6% YoY). Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both PYPD (31.1/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SRZN leads the Growth & Scale pillar: PYPD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). On trailing 12-month operating scale, PYPD generates N/A in USD-normalized revenue versus $11M for SRZN. In operating R&D and SG&A reinvestment, PYPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.

SRZN screens cheaper on headline valuation multiples. PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PYPD (-243.6% ROE) versus SRZN (-62.8% ROE) capital efficiency.

In options market volatility and institutional positioning, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.88β · 59% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.